Brinzolamide + Timolol MaleateThird Party Manufacturing in India

Brinzolamide + Timolol Maleate works by simultaneously suppressing aqueous humor secretion via two distinct pharmacological pathways. Brinzolamide reduces fluid secretion by blocking carbonic anhydrase enzyme activity in the ciliary processes, while timolol blocks beta-adrenergic receptors to further minimize fluid production. They work together to help the body control elevated intraocular pressure. Unlike separate drop administrations, this combination minimizes preservative exposure to the ocular surface. It is highly effective and well-tolerated.

Therapeutic Uses

• Refractory Open-Angle Glaucoma: Prescribed for patients requiring multi-mechanism treatment to achieve targeted intraocular pressure reductions.
• Ocular Hypertension Management: Used to manage high fluid pressures that do not respond to single-agent beta-blockers or prostaglandin analogs.

Why Manufacturers Choose Brinzolamide + Timolol Maleate

Brinzolamide + Timolol Maleate third party manufacturing in India is highly favored by pharmaceutical distributors due to excellent patient compliance rates and steady chronic-use market demand. Celesta oversees the rigorous formulation requirements through partner facilities that are WHO-GMP certified, ensuring optimal viscosity, particle size, and sterile batch repeatability. Adding this combination to your ophthalmic line provides an authoritative product offering manufactured under international WHO-GMP protocols.